Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six years and above having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene. Alyftrek is a combination of three drugs — vanzacaftor (a CFTR potentiator), deutivacaftor (a CFTR corrector) and tezacaftor. The…